How do detemir and glargine compare when added to oral agents in insulin-näve patients with type 2 diabetes mellitus?

Jennifer B Marks

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.

Original languageEnglish
Pages (from-to)490-491
Number of pages2
JournalNature Clinical Practice Endocrinology and Metabolism
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Type 2 Diabetes Mellitus
Insulin
Hypoglycemia
Hypoglycemic Agents
Weight Gain
Blood Glucose
Fasting
Appointments and Schedules
Insulin Glargine
Glucose
Therapeutics

Keywords

  • Basal insulin
  • Detemir
  • Glargine
  • Glycemic control
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

How do detemir and glargine compare when added to oral agents in insulin-näve patients with type 2 diabetes mellitus? / Marks, Jennifer B.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 4, No. 9, 01.09.2008, p. 490-491.

Research output: Contribution to journalArticle

@article{ae74d50c922640a0862c44a4e8fcb22f,
title = "How do detemir and glargine compare when added to oral agents in insulin-n{\"a}ve patients with type 2 diabetes mellitus?",
abstract = "In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-n{\"a}ve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45{\%} of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.",
keywords = "Basal insulin, Detemir, Glargine, Glycemic control, Type 2 diabetes mellitus",
author = "Marks, {Jennifer B}",
year = "2008",
month = "9",
day = "1",
doi = "10.1038/ncpendmet0900",
language = "English",
volume = "4",
pages = "490--491",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - How do detemir and glargine compare when added to oral agents in insulin-näve patients with type 2 diabetes mellitus?

AU - Marks, Jennifer B

PY - 2008/9/1

Y1 - 2008/9/1

N2 - In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.

AB - In this Practice Point commentary, I describe the findings and limitations of a 52-week, open-label, noninferiority, head-to-head comparison study of the basal insulin analogs detemir and glargine. Rosenstock et al. enrolled 582 insulin-näve individuals with type 2 diabetes mellitus inadequately controlled with oral antidiabetic agents. Participants were randomly allocated to receive either detemir or glargine, titrated to a target fasting plasma glucose level ≤6 mmol/l in the absence of hypoglycemia. Detemir was administered once-daily or (if needed) twice-daily to control predinner blood glucose levels, whereas glargine was administered only once-daily. Comparable improvements in glycemic control were observed in the two treatment groups. By contrast, less weight gain occurred with detemir than with glargine. Nonetheless, higher levels of detemir than glargine were required to achieve these beneficial effects and only 45% of patients in the detemir group remained on the once-daily dosing schedule. The implications of these observations for clinical practice are discussed.

KW - Basal insulin

KW - Detemir

KW - Glargine

KW - Glycemic control

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=50049114676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049114676&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0900

DO - 10.1038/ncpendmet0900

M3 - Article

C2 - 18594486

AN - SCOPUS:50049114676

VL - 4

SP - 490

EP - 491

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 9

ER -